The humoral branch of the immune response has an important role in acute and chronic allograft dysfunction. The CD40/CD40L costimulatory pathway is crucial in B-and T-alloresponse. Our group has developed a new small interfering RNA (siRNA) molecule against CD40 that effectively inhibits its expression. The aim of the present study was to prevent rejection in an acute vascular rejection model of kidney transplant by intra-graft gene silencing with anti-CD40 siRNA (siCD40), associated or not with sub-therapeutic rapamycin. Four groups were designed: unspecific siRNA as control; sub-therapeutic rapamycin; siCD40; and combination therapy. Long-surviving rats were found only in both siCD40-treated groups. The CD40 mRNA was overexpressed in control grafts but treatment with siCD40 decreased its expression. Recipient spleen CD40+ B-lymphocytes were reduced in both siCD40-treated groups. Moreover, CD40 silencing reduced donor-specific antibodies, graft complement deposition and immune-inflammatory mediators. The characteristic histological features of humoral rejection were not found in siCD40-treated grafts, which showed a more cellular histological pattern. Therefore, the intra-renal effective blockade of the CD40/CD40L signal reduces the graft inflammation as well as the incidence of humoral vascular acute rejection, finally changing the type of rejection from humoral to cellular. Gene Therapy (2011) 18, 945-952;
INTRODUCTION
The humoral branch of the immune response has an important role in both acute and chronic allograft rejection. 1, 2 The appearance of alloantibodies after renal transplantation is a critical setback that results in allograft loss. 1 Ligation of CD40 on B-cells is crucial for antibody production, 3 which can be inhibited or delayed by the blockade of the CD40/CD40L pathway. 2, 4, 5 The costimulatory molecule CD40 is constitutively expressed on a wide variety of cells. 3, [6] [7] [8] [9] Its ligand, CD40L, is also expressed more broadly than initially believed 3, 5, 6 . In renal transplantation, CD40 is overexpressed on tubular epithelial cells (TECs), macrophages and T-cells. 10 CD40 expression is homogeneous in the tubulo-interstitium in all grades of acute rejection, whereas in grafts suffering acute vascular rejection, grades II and III, it is strongly expressed on endothelial cells. 11 Vascular damage involves strong activation of the endothelium and it is well known that CD40 actively participates in these processes. 6, 12 Systemic blockade of the co-stimulatory signal has been shown to reduce rejection and improve survival. 5, [13] [14] [15] [16] Exciting results using monoclonal antibody against CD40L, leading to long-term acceptance of renal allograft in non-human primates, have been reported. However, thromboembolic complications with this antibody have impeded its clinical development. 17, 18 Our group has developed a human small interfering RNA (siRNA) molecule against CD40 that effectively inhibits its expression. In vitro silencing of CD40 combined with transcriptional profiling has demonstrated its participation in several downstream cellular processes involved in acute humoral rejection, such as coagulation, endothelial cell activation and inflammation. 12, 19 The aim of the present study was to assess the in vivo therapeutic efficacy of intrarenal graft silencing of CD40 with a newly developed siRNA anti-rat CD40 in a model of humoral-like acute vascular rejection. 20 Aware of the need for combined therapy in studies blocking the CD40/CD40L pathway, we also assessed the effects of the addition of sub-therapeutic doses of rapamycin.
The in vivo results shown in this study demonstrate the effectiveness of pre-transplant local silencing of CD40, blocking the CD40/CD40L co-stimulatory signal, as a strategy to prevent humoral rejection switching to a more cellular pattern.
RESULTS

Selection and characterization of effective anti-rat CD40 siRNAs
Nine siRNAs were designed and generated to target different positions within the coding region of rat CD40 mRNA ( Table 1) .
The RNA interference efficacy of each of the nine synthesized siRNAs was tested in HEK-293 cells using the GeneEraser Luciferase Suppression-Test System (Stratagene, La Jolla, CA, USA). These siRNAs were co-transfected into HEK-293 cells along with a luciferase/CD40 fusion construct. Luciferase activity was determined at 2 days post-transfection ( Figure 1) .
Five of the designed siRNAs had significant knockdown efficacy, although the most potent silencing efficiency (82-84%) was achieved with the siRNAs TNFRSF5-1 and TNFRSF5-2 ( Figure 1 ). Thereby, we chose siRNA TNFRSF5-2 (renamed as siCD40) for the subsequent in vivo study.
Effect of CD40 silencing in renal function and survival NoTreat animals developed severe renal insufficiency from the 5th day post-transplantation dying before 9 days. Treatment with 0.5 mg kg À1 per day of rapamycin was unable neither to avoid renal insufficiency nor to increase survival ( Figure 2 ). Seven long-surviving rats were found in both siCD40-treated groups. Five out of those (three in the siCD40 group and two in the siCD40-Rp group) displayed stable chronic renal insufficiency (sCr around 250-300 mmol l À1 ), surviving for 39, 48, 53, 57 and 57 days. The remaining two rats (siCD40-Rp group) achieved indefinite survival with stable renal function throughout the study (sCr 100 ¼69 and 130 mmol l À1 ) (Supplementary Figure SI-4) .
Effect of CD40 silencing in the rejection pattern Conventional histology of NoTreat grafts showed a variable degree of tubule-interstitial damage, perivascular edema and hemorrhage, fibrinoid necrosis either in the vessel wall or in glomeruli, endothelial denudation and cell infiltration mainly composed by polymorphonuclear cells but few lymphocytes; all these features were indicative of acute vascular humoral rejection (Figure 3a) .
Grafts treated with sub-therapeutic rapamycin displayed mixed features of both cellular and humoral rejection: there was notable cell infiltration in all renal parenchyma including the vessels, with the characteristic humoral signs of karyorrhexis and activated endothelium in vessel walls (Figure 3b ).
Only 12% of both siCD40-treated groups displayed features of acute vascular humoral rejection. In all, 49% of grafts presented cellular rejection, occasionally affecting vessels and more frequently displaying slight tubulitis and interstitial infiltrate mainly composed by lymphocytes (17% grade III, 3% grade IIA, 5% grade IA and 24% borderline). Altogether, under light microscopy the siCD40-treated Table 1 Sequence composition and target localization of the siRNAs designed to screen for efficient rat CD40 mRNA silencing   siRNA anti-rat CD40  Rat CD40 mRNA targeted region  Sequence   siRNA-2  124-145  5¢-ACAGUACCUCCAAGGUGGCUU-3¢ 3¢-UUUGUCAUGGAGGUUCCACCG-5¢  siRNA-4  171-192  5¢-ACCGACUAGUUAGCCACUGUU-3¢ 3¢-UUUGGCUGAUCAAUCGGUGAC-5¢   siRNA-6  212-233  5¢-UGCCAACCGUGCGACUCAGUU-3¢ 3¢-UUACGGUUGGCACGCUGAGUC-5¢  siRNA-10  290-251  5¢-CUCAAUCAAGGGCUUCAGGUU-3¢ 3¢-UUGAGUUAGUUCCCGAAGUCC-5¢   siRNA-12  299-320  5¢-GGGCUUCAGGUUAAGAAGGUU-3¢ 3¢-UUCCCGAAGUCCAAUUCUUCC-5¢  siRNA-21 517-538 5¢-GUGUCAUCCAUGGACAAGCUU-3¢ 3¢-UUCACAGUAGGUACCUGUUCG-5¢
siRNA TNFRSF5-1 157-175 5¢-GCUCUUGAGAAGACCCAAUUU-3¢ 3¢-GTCGAGAACUCUUCUGGGUUA-5¢ siRNA TNFRSF5-2 193-211 5¢-GGCGAAUUCUCAGCUCACUUU-3¢ 3¢-GTCCGCUUAAGAGUCGAGUGA-5¢ siRNA TNFRSF5-3 66-84 5¢-GUGUGUUACGUGCAGUGACUU-3¢ 3¢-GTCACACAAUGCACGUCACUG-5¢ siRNA-C -5¢-ACUACAAGACUCGUGACCAUU-3¢ 3¢-UUUGAUGUUCUGAGCACUGGU-5¢
Abbreviation: siRNA, small interfering RNA. Local silencing of CD40 changes rejection pattern E Ripoll et al animals presented a more cellular and apparently chronic pattern of rejection (Figures 3c and d) .
Five out of the seven long-surviving rats, treated with siCD40, displayed only grade 1 tubulitis and interstitial infiltrate with some degree of fibrosis. The other two rats, which achieved indefinite survival, displayed a normal histology in one case, and only grade 2 tubulitis with interstitial infiltrate in the other.
In the NoTreat group, most of the grafts were C4d + and IgG + in peritubular capillaries, while CD40 silencing reduced the positivity for these humoral parameters ( Table 2 ).
In addition, donor-specific antibodies (DSA) were evident in 83% of NoTreat animals whereas serum from non-transplanted WA rats did not present pre-formed DSA against BN splenocytes (1.77±0.53% DSA+ cells). Treatment with either rapamycin or siCD40 partially reduced the DSA. Importantly, the combination of both treatments reduced not only the presence of DSA but also the percentage of positive cells (Table 2 and Supplementary Figures SI-1 and SI-3) .
Some DSA-positive animals did not show histological features of humoral rejection. However, all grafts displaying a histological pattern of antibody-mediated acute humoral rejection were DSA-positive. Most of the DSA-negative animals presented cellular rejection.
Local and systemic CD40 expression All renal structures expressed variable CD40+ immunostaining: TECs, vessel SMCs and glomeruli. When CD40 was silenced, protein expression disappeared in glomeruli and vessels, and TEC immunostaining diminished (not shown).
CD40 gene expression in NoTreat grafts was overexpressed 20-fold compared with control non-transplanted kidneys. Rapamycin partially reduced CD40 expression. Intra-graft gene silencing effectively reduced CD40 expression to syngeneic values (3.45±0.75). The addition of siCD40 plus rapamycin did not further reduce CD40 gene expression (Table 3) To evaluate the effect of intra-graft CD40 silencing on the systemic B-cell response, we used FACS to quantify the percentage of CD45RA+ (B-cells), CD40+ and double labelled splenocytes at the moment of sacrifice. Results showed that both groups treated with siCD40 had fewer B+ splenocytes than the NoTreat group. Furthermore, the siCD40-treated group expressed the lowest percentage of CD40+/CD45RA+ splenocytes, and supplementation with rapamycin did not reduce this cell population further (Table 2 Intra-graft expression of mediators Intra-graft gene expression of TLR3, TLR4 and the downstream intermediate MyD88 was reduced in both siCD40-treated groups, particularly in the siCD40-Rp group. In contrast, its expression was strongly activated in the NoTreat group. Complement regulators CFH and CFI were also downregulated in all treated groups, especially in the combined therapy (Table 3 We previously showed a clear upregulation of apelin in endothelial cells as a consequence of siRNA-mediated CD40 silencing in vitro. 12 In the present in vivo study we confirm a downregulation of apelin gene expression in NoTreat animals which, as shown, had severe acute vascular damage. Upon CD40 silencing, apelin expression returned to values similar to syngeneic rats, but this effect was not observed in rapamycin treatment (Figure 4) .
Analysis of the local pro-inflammatory status in NoTreat rats showed the expected cytokine overexpression ( Table 3 ). The antiinflammatory IL-11 was overexpressed by CD40 silencing, following a similar expression pattern to apelin in the treated groups. In contrast, IL15 expression was specifically downregulated upon CD40 silencing; whereas IL-7R expression was reduced in all treated grafts (Table 4) . Further staining of grafts for IL-7R expression showed preferential localization in tubular epithelial and vascular endothelial cells (Figure 3e ). In Rp group there was a slight decrease in IL-7R expression (Figure 3f ), while both siCD40-treated groups showed a clear reduction in tubuli and almost null expression in the vessels (Figures 3g and h) .
Finally, downstream of the inflammatory cascade, the gene expression of the nuclear factor kB was reduced by all treatments, particularly when CD40 silencing was combined with the subtherapeutic dose of rapamycin (Table 3 and Supplementary Figure SI-3) . Accordingly, nuclear factor kB nuclear translocation was reduced in siCD40-treated grafts (Table 4 ). In contrast, it was translocated from cytoplasm to nuclei in the NoTreat and Rp groups, especially in interstitial infiltrate and vascular endothelial cells.
DISCUSSION
The present study was designed as proof of concept to assess the potential intra-graft role of our CD40-siRNA molecule. Local silencing of CD40 through a single dose at recovery of organs, in a model of kidney transplantation with severe humoral vascular damage, caused a shift in the rejection pattern, reduced circulating DSA and improved rat survival. Moreover, this local treatment was clearly effective blocking graft CD40 gene expression, leading to a changed immunological environment in the graft. We wanted to know whether modulating locally the immune graft state redounded in better acceptance. The 14% (3 out of 21) of graft viability gives a nice positive answer to this question. It was not the aim of this study to avoid acute rejection and achieve 100% survival. If this was the case, then we would have assayed a more sustained CD40 silencing and/or we would have probably employed a weaker model. In fact, the present is a virulent model of acute rejection and the treatment utilized is too punctual. We knew in advance that a single intra-graft pre-transplant injection would not be sufficient to prevent mortality. However, we made use of this approach to test the potential power of our siCD40 molecule.
We added a sub-therapeutic dose of a well-known immunosuppressant to synergize with the CD40/CD40L co-stimulatory pathway blockade. This dose of rapamycin used here in monotherapy was clearly sub-optimal for preventing rejection. However, its combination with CD40 silencing was sufficient to significantly delay rejection and to prolong survival. Indeed, two rats achieved indefinite survival with this combined therapy. Our interpretation is that intra-graft CD40 silencing switched the strong graft rejection to one more easily controlled with conventional immunosuppression. Thus, combining CD40 intra-graft silencing with reduced doses of mTOR inhibitors might constitute an useful immunosuppressive strategy in the future.
In the early phase after transplantation, rapid recognition and adequate treatment of the diverse mechanisms of allograft immuneinflammatory response are decisive. 21 As Sacks and Zhou suggested 22 , donor kidney pre-treatment appears as a valid strategy to modify the sensitivity of donor kidneys, and may have application in human renal therapy. Our present strategy using intra-graft CD40 silencing reduces the humoral vascular acute rejection incidence, shifting towards a cellular rejection pattern. Under light microscopy, NoTreat kidneys evidenced a typical pattern of humoral vascular rejection. In both siCD40-treated groups, not only inflammation was prevented but also the type of rejection had changed. This rejection shift was also evidenced by the reduction in complement deposits in the peritubular capillaries of siCD40-silenced groups. In addition, the expression of the complement regulatory proteins CFH and CFI was reduced inside the treated kidneys, indicating a lower local activation of complement as a consequence of CD40 silencing. It is well known that intra-graft Local silencing of CD40 changes rejection pattern E Ripoll et al synthesis of complement can have a profound effect on acute allograft rejection. 23, 24 Alloantibody-mediated humoral rejection results from high-titter de novo DSA formation, leading to a high risk of early graft loss. 1 Our model was previously described as 'humoral-like' as it displays vascular damage with fibrinoid necrosis and perivascular edema. 21 Now we confirm that in this model, in which pre-transplant DSA were not present in WA rats, there was a massive formation of DSA probably due to early peri-transplant B-cell activation. [25] [26] [27] In this highly stringent model, intra-graft CD40 silencing was unable per se to reduce circulating DSA, as expected from local treatment. However, when combined with a sub-therapeutic dose of rapamycin, an additive systemic reduction was found. A similar outcome has recently been reported with a high sensitization skin grafting mouse model, in which selective systemic blockade for CD154 predominantly impaired the generation of humoral immunity. 28 
Local silencing of CD40 changes rejection pattern E Ripoll et al
Interactions between costimulatory ligands and their receptors are crucial for the induction and regulation of innate and adaptive immune responses. As a consequence of cell damage, injured cells release certain molecules that act as endogenous ligands for TLR4, which, upon activation, signal through MyD88. [29] [30] [31] Moreover, it is well known that double-stranded RNA molecules are exogenous ligands for TLR3. In our grafts, locally injected with the siCD40, TLR3 expression was reduced, which seems to discard the possibility that either this molecule or the methodology used activated the innate immune response. Furthermore, the lower expression of TLR4 and MyD88 is consistent with a modulation of the innate immune response and indeed would favor the reduction in tissue damage.
The graft inflammatory background was locally modulated toward an anti-inflammatory situation by CD40 silencing. IL15 and IL7R act as pro-inflammatory cytokines that support lymphocyte proliferation and activation. IL15 expression in TECs is upregulated by CD40L and correlates with acute graft rejection. 32 As expected, CD40 silencing reduced IL15 production, probably influenced by the direct blockade of CD40/CD40L signalling and the consequent reduced activation of NFkB. 32 On the other hand, we observed a higher local expression of the anti-inflammatory IL-11. There is in vivo evidence that IL-11 treatment enhanced recipient survival by suppressing cytokine production. [33] [34] [35] This anti-inflammatory effect is mediated by its ability to block the nuclear translocation of NFkB. In our siCD40-treated grafts, NFkB expression was downregulated and its translocation to the nucleus was blocked. This could be an indirect consequence of CD40 silencing through IL-11, or a direct effect of this silencing on NFkB, as we previously showed in our in vitro study. 12 A plausible explanation for the benefits of our local CD40 silencing could be its targeting of the direct pathway. Local silencing of the donor kidney may involve not only dendritic cells but also nonprofessional resident APC participating in the direct pathway. Both T-and B-cell adaptive immune responses must be controlled to prevent sensitization to alloantigen and to prolong graft survival. 28 Although CD40-CD40L blockade predominantly impairs B-cell responses, it is not sufficient to completely block T-cell activation. 28 This might explain why a single local dose of siCD40, even when combined with the sub-therapeutic dose of rapamycin, was insufficient to induce indefinite survival in most of the treated rats. Clearly, our local treatment with siCD40 only blocks intra-graft CD40 expression. However, this local treatment had a systemic effect on splenocytes, reducing the number of B-cells and, particularly, the number of CD40+ B-cells. It could be hypothesized that the primary lymphoid organs produce fewer B-cells and consequently fewer circulating B-cells and antibodies 28 as a consequence of the reduced intra-graft immune-inflammatory response induced by local siCD40 treatment.
We previously showed that the CD40/CD40L dyad influences a myriad of pathways involved in graft vasculopathy. 12 One of the most strikingly downregulated mediators was the vasoactive peptide apelin. In this study, we corroborate the relationship between CD40, apelin and graft vascular immune-inflammation. Thus, NoTreat animals showed inhibition of apelin expression, but its expression levels were similar to those in non-transplanted kidneys when CD40/ CD40L was blocked. Apelin is expressed at various sites within the cardiovascular system and in kidney endothelium. [36] [37] [38] [39] [40] Malyszko et al. 36 recently showed low apelin amounts in allograft recipients. Those patients showed pronounced endothelial damage together with an increase in inflammatory markers, suggesting that apelin may be associated with inflammation. Interestingly, when CD40 silencing was associated with rapamycin, it failed to maintain normal apelin levels. Though rapamycin did not modify the effect of exogenously administered apelin in experimental myocardial reperfusion injury, 37 it did inhibit apelin in our model. This may be due to the fact that rapamycin and apelin have opposite actions on intracellular signalling, whereas apelin activates the phosphorylation of p70S6K, 38 through the phosphorylation of STAT3, 39 rapamycin inhibits apelin-mediated phosphorylation. 38, 41 A similar effect could account for the siCD40-induced gene overexpression of IL11, which was also inhibited by rapamycin.
Present in vivo results show the effectiveness of pre-transplant local silencing of CD40 as a strategy to prevent antibody-mediated rejection, changing it into a more cellular pattern. In terms of clinical importance, strategies of cellular rejection treatment are generally well controlled with conventional immunosuppression, whereas humoral rejection continues to be an unresolved drawback. Yet this local treatment may require systemic siCD40 delivery to achieve indefinite survival, as that would block both the direct and indirect antigenpresentation pathways. These initial results open the door to clinical trials silencing CD40 not only in the transplantation setting, but also in other autoimmune and inflammatory diseases where CD40, B-cells and antibodies have a key role.
MATERIALS AND METHODS
siRNA design and screening siRNA duplexes targeting the partial rat CD40 mRNA sequence (GenBank NCBI, Bethesda, MD, USA, Accession no. AF241231) were designed as previously described (www.mpibpc.gwdg.de/abteilungen/100/105/sirna.html). For the initial screening, six siRNAs were synthesized by in vitro transcription (Silencer TM siRNA construction kit, Ambion, Austin, TX, USA), and three more (TNFRSF5-1, TNFRSF5-2 and TNFRSF5-3) were chemically synthesized (Cenix BioScience; Silencer pre-designed siRNAs, Ambion). A scrambled nonsilencing siRNA was used as control for off-target effects.
To assess the rat CD40 mRNA silencing efficiency of siRNA molecules, we employed the GeneEraser Luciferase Suppression-Test System (Stratagene, La Jolla, CA, USA). A 547pb CD40 partial coding sequence was cloned into the 3¢UTR of the luciferase gene to form the targeting vector pTarget-luc-CD40. In vitro transfection of siRNAs (100 nM) was performed in HEK-293 cells using Oligofectamine (Invitrogen, Paisley, UK). After 6 h, the cells were transfected with pTarget-luc-CD40 (400 ng DNA; Polyfect Transfection Reagent, Qiagen, Hilden, Germany). After 48 h of incubation, the luciferase activity from lysates was determined (Luciferase Assay System, Promega, Madison, WI, USA; Luminometer TD-20/20, Turner Designs, Sunnyvale, CA, USA). For normalization of transfection efficiency, co-transfected pCMV-bgal was determined (up to 500 ng DNA).
Protocol of siRNA transfer to renal tissue
To set up the siRNA transfer protocol we performed preliminary studies evaluating the siRNA dose, carrier vector and administration procedure. The protocol that offered optimal tissue transfer was as follows. Chemically synthesized siRNA duplexes (Qiagen) were dissolved in diethylpyrocarbonate water. Following renal washing with 1 ml of EuroCollins solution at 4 1C, donor kidneys were intra-arterially infused with 30 ug of either siCD40 or control unspecific siRNA duplex in a final 1 ml volume of isotonic saline solution. Immediately after siRNA infusion, kidneys underwent electroporation held with a tweezers-type electrode. The electroporation protocol (six pulses of 20 ms for each, 1 Hz frequency, at 100 V cm À1 ) was applied twice per kidney to ensure that the whole tissue was covered by the tweezers-type electrode. (See Supplementary information).
Animals and surgical transplantation technique
For functional assessment of CD40 silencing, inbred male Wistar-Agouti rats (250 g BW) received an allogeneic kidney from Brown-Norway rats (250 g BW) (Charles River by Harlan UK Limited, Bicester, UK). Kidneys were preserved 
Treatments and groups. Follow-up
NoTreat group: unspecific siRNA as control (n¼16); Rp group: daily oral subtherapeutic rapamycin (0.5 mg Kg À1 , Sirolimus, Wyeth, Madrid, Spain) for the first 15 days after transplantation (n¼14); siCD40 group: siCD40 (n¼21); and siCD40-Rp group: siCD40 and sub-therapeutic rapamycin (n¼21). Serum creatinine (sCr, mmol l À1 ) was determined by Jaffe's reaction (Olympum Autoanalyzer, Hamburg, Germany) every 2 days beginning the day after surgery. For the survival study, rats were ideally followed for 100 days. The indefinite survival was established at this time point. Upon sacrifice, grafts were excised and processed for histological and molecular studies.
Histological studies
Coronal 1-2 mm-thick slices of graft kidneys were fixed in buffered formalin, dehydrated and embedded in paraffin. For light microscopy, 3-4 mm-thick tissue sections were stained with hematoxylin-eosin and periodic acid-Schiff. A pathologist blinded to the treatment groups assessed all sections for tubulitis, interstitial infiltration, vasculitis, glomerulitis, mesangiolysis, acute tubular necrosis, peritubular capillary infiltration, capillary thrombosis, intimal arteritis, fibrinoid necrosis, transmural infiltration, endothelial denudation and hemorrhage, following the Banff criteria for acute/active lesion scoring. 42 
Immunohistochemistry
Representative paraffin-embedded tissue sections were immunoperoxidasestained for CD40 (1:50; Research Diagnostics Inc., Flanders, NJ, USA), NFkB p65 subunit (1:1000; Abcam PLC, Cambridge, UK), apelin (1:500; Phoenix Pharmaceuticals, Belmont, CA, USA), IL-7R (1:50; Santa Cruz Biotechnology, Santa Cruz, CA, USA) and C4d (1:30; Biomedica Gruppe, Vienna, Austria) and immunofluorescence-stained for IgG (1:300; Sigma, Madrid, Spain). Negative controls were performed by immunostaining-matched serial sections without the primary antibodies. The immunoperoxidase-stained samples were revealed with diaminobenzidine (D-5637, Sigma) and counterstained with hematoxylin. For IgG, samples were directly observed under fluorescence light microscopy.
C4d and IgG (assessed in peritubular capillaries), apelin and IL-7R were semi-quantitatively scored: 0 denoted negative staining, 1 positive staining in o25% of the sample, 2 positive staining in 25-50%, 3 positive staining in 50-75%, and 4 positive staining in 75-100%. NFkB p65 immunostaining was considered positive when it was located inside the nuclei of different cells (TECs, VECs and interstitial infiltrate). CD40 immunostaining was only used to localize the protein expression without further semi-quantification.
Quantification of gene expression in renal grafts
For molecular studies, the kidney was immediately frozen in liquid nitrogen and stored at À80 1C. Total RNA was extracted and reverse-transcribed to complimentary DNA as previously described. 43 Negative controls for reverse transcription were carried out using distilled water. Tissue expression levels for CD40 and other immune-inflammatory mediators were quantified by TaqMan real-time PCR (ABI Prism 7700, Applied Biosystems, Madrid, Spain) using the comparative C T method (Applied Biosystems).
PCR reactions and amplification were performed as previously described. 43 Pooled values of healthy non-transplanted kidneys were used as the reference value. Results were expressed as 'many fold of the unknown sample' with respect to the reference value (arbitrary units).
Quantification of circulating donor-specific antibodies
The presence of circulating DSA class-I was quantified on recipient serum samples incubated with donor spleen cells and measured by flow cytometry. Plasma samples were collected at the moment of sacrifice. Donor splenocytes were isolated from a Brown-Norway rat spleen by Ficoll (GE Healthcare, Uppsala, Sweden) density gradient and freshly used. Different controls were added: serum from non-transplanted Wistar-Agouti rat as naïve; serum from a transplanted WA rat with high anti-human leukocyte antigens antibodiy titer as positive control, and splenocytes from Lewis rat as negative control.
Briefly, 5Â10 5 splenocytes were incubated with 25 ml of recipient serum for 30 min at room temperature, washed in phosphate-buffered saline, incubated in the dark (30 min, 4 1C) with a 1:25 mix of anti-CD3 (eBioscience, Ltd, Hatfield, UK) and anti-IgG Fc portion (Jackson Immuno Research, West Grove, PA, USA), fixed with 1% paraformaldehyde and analyzed by flow cytometry. Fluorescence increase of 15% with respect to the negative control was considered as positive. Results were expressed as percentage of positive cells with respect to the total number of CD3+ spleen cells.
Quantification of the CD40-and CD45RA-positive population in the spleen At sacrifice, the recipient's spleen was harvested in phosphate-buffered saline. The splenocytes were isolated by Ficoll density gradient and crio-preserved at À180 1C.
To quantify the percentage of CD40+ and CD45RA+ splenocytes, cells were thawed and recovered by standard methods. In all, 5Â10 5 splenocytes were incubated in the dark (20 min, 4 1C) with antibodies (5 ml CD40 and 2ml CD45RA, BD Pharmingen, Madrid, Spain). After washing with phosphatebuffered saline, 7-amino-actinomycin D (1:10) was added to control cell viability. Cells were analyzed by flow cytometry. Results are expressed as mean percentage of positive cells to the total number of splenocytes.
Statistical analysis
Overall survival was analyzed using the Log Rank test. Serum creatinine differences at any time point, gene expression, plasma cytokine levels and DSA titters were analyzed by analysis of variance followed by Scheffe's test. For histological parameters and DSA presence, w 2 P-value was calculated from the contingency table. Semi-quantitative immunostaining was analyzed through the non-parametric Kruskal-Wallis test. Values of Po0.05 were considered as statistically significant. Data are presented as mean±s.e.m.
